Arllecta Group Highlights the Need for Shift from Symptomatic Treatment to Etiological Treatment to Combat Cancer
Singapore, 28th Feb 2025 – As part of their longevity project, the Arllecta Group research team led by Egger Mielberg is using special computer programs, sense, and antisense algorithms from sense theory finding new approaches to molecular genetic analysis and the creation of new biochemical maps of the entire organism.
Egger Mielber of the Arllecta Group has recently published his research paper titled Longevity or Cancer: what’s first? online. The study comes after extensive in-depth research conducted by the team for three years, studying 10 types of cancer, the longevity elixir, and the relationship between the two. The findings propose four new biochemical and molecular patterns to help medics find cancer early before it has spread, with a 98.8% chance of success.
The research challenges the traditional cancer detection methods for its symptomatic dependence. The paper explores more than the symptoms; the approach should target the cancer’s causes and detect them in the neonatal stages of development.
The breakthrough presents critical insights that pave the way for continued research and experimentation in the field, as noted by the Arllecta research team during a conversation with the local media team. The study explores a new concept called decarcinogenesis, which describes how cancer cells can revert to their original, healthy state. This research underscores the profound impact that incurable diseases such as cancer have on overall life expectancy, highlighting the urgent need for early intervention in cancer prevention and treatment. The findings stress the importance of addressing these challenges now and for future generations.
The Arllecta Group has built a solid reputation in the technology sector. With more than 12 years of expertise in machine learning, artificial intelligence, and mathematical modeling, the organization offers self-learning and predictive networks tailored for business solutions in the global market. Their research is consistently praised for its reliability and precision. For this research, they studied advanced AI algorithms in the new age based on their sense theory to learn about genes and body chemistry in ways not done before.
‘While swinging between longevity and cancer, we tried to push for an answer, find a relationship, and spot contrasting elements that would provide us with concluding points for our research. In summary, we concluded that building a skyscraper without a quality concrete foundation is impossible, so we need cancer out of the equation to thrive human life.’
— Research Team, Arllecta Group.
The research paper introduces a fresh cancer treatment model and establishes a foundation for further research. With progress made in the field, the Arllecta research team hopes to make cancer curable at early stages and ensure quality human life.
For more details and information, please visit https://www.arllecta.com/.
The complete research paper is available to read for free at https://www.researchgate.net/publication/388921588_Longevity_or_Cancer_what’s_first.
Media Contact
Organization: Arllecta Group
Contact Person: Igor Mikhailovskii
Website: https://www.arllecta.com/
Email: Send Email
Country: Singapore
Release Id: 28022524531